Wedbush Reiterates Neutral on 2seventy bio, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates a Neutral rating on 2seventy bio (NASDAQ:TSVT) and maintains a $5 price target.

March 18, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst David Nierengarten reiterates a Neutral rating on 2seventy bio with a $5 price target.
The reiteration of a Neutral rating and maintenance of a $5 price target by Wedbush suggests no significant short-term catalysts expected to drive the stock price significantly higher or lower. The analyst's view appears to be that the stock is fairly valued at its current level.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100